Compositions and Methods for Treating Spinal Muscular Atrophy

Abstract

The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered in the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated.

1 . A method for treating spinal muscular atrophy in a primate with spinal muscular atrophy, comprising administering to the spinal cord and/or cisterna magna of the primate at least 1×10 12  genome copies of a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a primate SMN; wherein the rAAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV10, AAVrh10, AAV11, or AAV12 serotype capsid. 
     
     
         2 . A method for ameliorating a symptom of spinal muscular atrophy in a primate, comprising administering to the spinal cord and/or cisterna magna of the primate at least 1×10 12  genome copies of a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a primate SMN; wherein the rAAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV10, AAVrh10, AAV11, or AAV12 serotype capsid. 
     
     
         3 . The method of  claim 2 , wherein the symptom of spinal muscular atrophy is one or more of muscle wasting, inability to achieve motor milestones, inability to sit, inability to walk, paralysis, respiratory dysfunction, bulbar dysfunction, motor neuron cell loss and neuromuscular junction pathology. 
     
     
         4 . A method for delivering a heterologous transgene encoding a primate SMN in a motor neuron in a primate with spinal muscular atrophy, comprising administering to the spinal cord and/or cisterna magna of the primate at least 1×10 12  genome copies of a recombinant adeno-associated virus (rAAV) viral particle comprising a vector encoding a primate SMN; wherein the rAAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV10, AAVrh10, AAV11, or AAV12 serotype capsid. 
     
     
         5 . The method of  claim 4 , wherein at least 10-30% of the motor neurons in the lumbar, thoracic and cervical regions of the spinal cord are transduced and/or wherein at least 30% of SMN wild type levels are generated throughout the spinal cord. 
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 4 , wherein the rAAV is administered via direct injection into the spinal cord, via intrathecal injection, or via intracisternal injection. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 4 , wherein the rAAV is administered to one or more of a lumbar subarachnoid space, thoracic subarachnoid space and a cervical subarachnoid space of the spinal cord. 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 4 , wherein at least 3.5×10 11  genome copies per kg body weight at least 3.5×10 12  genome copies per kg body weight, at least 5×1012 genome copies per kg body weight, or at least 5×1013 genome copies per kg body weight of rAAV is administered to the primate; or wherein at least 2.5×10 12  genome copies or at least 1.25×10 13  genome copies are administered to the primate. 
     
     
         21 . The method of  claim 4 , wherein the vector comprises AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrh10, AAV11, or AAV12 serotype inverted terminal repeats (ITRs). 
     
     
         22 - 26 . (canceled) 
     
     
         27 . The method of  claim 4 , wherein the vector is a self-complimenting vector. 
     
     
         28 - 29 . (canceled) 
     
     
         30 . The method of  claim 4 , wherein the vector encodes a SMN-1 transgene operably linked to a promoter. 
     
     
         31 . The method of  claim 30 , wherein the promoter is capable of expressing the SMN-1 transgene in neurons of the spinal cord. 
     
     
         32 . (canceled) 
     
     
         33 . The method of  claim 4 , wherein the promoter comprises a human β-glucuronidase promoter or a cytomegalovirus enhancer linked to a chicken β-actin promoter. 
     
     
         34 .- 35 . (canceled) 
     
     
         36 . The method of  claim 4 , wherein the vector comprises a polynucleotide encoding the amino acid sequence of SEQ ID NO:1. 
     
     
         37 .- 38 . (canceled) 
     
     
         39 . The method of  claim 4 , wherein the primate is a human. 
     
     
         40 . The method of  claim 39 , wherein the human is a pediatric subject or a young adult. 
     
     
         41 - 46 . (canceled) 
     
     
         47 . The method of any one of  claim 4 , wherein the rAAV viral particle is in a pharmaceutical composition. 
     
     
         48 . (canceled)